Alhydrogel®

Alhydrogel®

Pharma

Information

Alhydrogel is a range of aluminium hydroxide gel products which have been specifically developed for use as an adjuvant in human and veterinary vaccines. The gel is a suspension of boehmite-like (aluminium oxyhydroxide) hydrated nano/micron size crystals in loose aggregates. The products have very low conductivity due to the absence of buffering ions. They have a positive charge at neutral pH and effectively adsorb negatively charged antigens. The primary purpose of the adjuvant in vaccines is to boost the antibody-mediated (Th2) immune response. Alhydrogel products can be combined with other adjuvant types (such as monophosphoryl lipids) to achieve a balanced Th1/Th2 immune response.
CrodaCroda International Plc, a specialty chemical company providing high purity and high quality excipients for drug and vaccine development, has recently strengthened their offering with the acquisition of a line of vaccine adjuvants. Providing customers with over 80 years of adjuvant expertise, Croda Vaccine Adjuvants (formerly Brenntag Biosector) has unprecedented industry experience as a vaccine adjuvant specialist. In addition to supplying industry renowned aluminium- and saponin-based adjuvants, including the well-known brands Alhydrogel®, Adju-Phos® and Quil-A®, Croda is committed to developing the next generation of adjuvant technology, with a robust innovation pipeline focusing on enhanced protein binding and immune-stimulating nanotechnology.

Log in